Yposkesi. (2/24/20). "Press Release: Yposkesi Welcomes Patrick Lansky as VP of US Sales & Marketing". Corbeil-Essonnes.

	Region	United States (USA)
	Organisation	Yposkesi (FR)
	Group	SK Group (Group)
	Organisation 2	Cobra Biologics (Group)
	Group	Charles River (Group)
	Product	contract manufacturing (biologicals)
	Product 2	adeno-associated viral vector (AAV vector)
	Person	Lansky, Patrick (Yposkesi 202002– VP US Sales + Marketing before Cobra Biologics + Vetter-Pharma + Atlhea Technologies
	Person 2	Lamproye, Alain (Yoskesi 201807 CEO before Novasep 201511 President of Biopharma Business Unit)

With 20 years’ biotech experience including a decade in CDMO cell and gene therapy, Mr. Lanksy is charged with forging bioprocessing partnerships with US biopharmaceuticals developers

Yposkesi, a leading Contract Development and Manufacturing Organization (CDMO) for preferred access and reserved capacity for cGMP grade viral vector production, today announces the appointment of Patrick Lansky as VP of US sales & marketing.

Mr. Lansky’s role is to develop strong partnerships with US companies working on cell and gene therapy projects, where the demand for Adeno-Associated Virus (AAV) and Lentiviral (LV) vectors continues to rise. Developing gene therapy products requires using vectors; bioengineered tools that deliver their modified genetic material into desired locations in the body, tissues and cells. Mr. Lansky will raise awareness of Yposkesi’s bioprocessing expertise and capabilities in AVV and LV, its current 400L capacity and the company’s new facility that will extend capacity to 2000L when it launches in 2022. This increased capacity will enable Yposkesi to address future needs for large-scale commercial batches.

“Yposkesi is delighted to welcome Patrick at a time when increasing numbers of cell and gene therapies are progressing from the laboratory to clinic,” said Alain Lamproye, CEO of Yposkesi. “Patrick has the skillset and strong track record to strengthen our presence in the US, home to the market leaders in cell and gene therapy developments. Beefing up our proximity to US clients and reinforcing our trusted relationships are key.”

Yposkesi has secured several important partnerships with US-based developers of cell and gene therapies over the last few years, such as Axovant Gene Therapies.

“I am very excited to join Yposkesi. As a spin-off from Genethon, it has world-class knowledge and expertise in cell and gene therapy bioprocessing,” said Patrick Lansky, US VP sales & marketing. “It’s state-of-the-art suspension processes for both AAV and LV, high-quality analytical services and capacity to manufacture at scale make it ideal to become the preferred partner for US gene therapy developers, especially those currently facing a bottleneck in manufacturing.”

The growth of this global market is forecast at a CAGR of over 24% during the period 2018–2024. Gene therapies are showing much promise in treating genetic disorders or preventing infectious diseases, marked by a rise in the number of approved or conditionally approved gene therapies around the world, according to industry reports. The driving demand for preclinical and clinical-grade gene delivery vectors, with some gene therapies entering commercialization, requires the availability of more scalable manufacturing capacity.

Mr. Lansky joined Yposkesi from Cobra Biologics, where he worked as director of business development, Western US, for eight years. His 20 years’ experience in biotech includes posts in business and sales management roles at Vetter-Pharma Fertigung, Althea Technologies and Sartorius Stedim Biotech. He began his career as a research associate for IDEC Pharmaceuticals, which became Biogen.

About Ypsokesi

Yposkesi is a leading Contract Development & Manufacturing Organization (CDMO) for gene therapy vector manufacturing. Created in November 2016 in Corbeil-Essonnes (France) by AFM-Telethon and the SPI fund managed by Bpifrance, Yposkesi provides integrated services covering bioprocess development (USP & DSP) from small/pilot to large-scale production, analytical development, GMP manufacturing of lentiviral and AAV vectors and regulatory support. Its current facility consists of a 50,000ft2 (approx. 5,000m2) building, operating multiple manufacturing suites for bulk drug substance and Fill&Finish. By 2022, Yposkesi will increase its global footprint to 100,000ft2 (approx. 10,000m2) with a second large-scale facility designed for EMA and FDA compliance. Capitalizing on the more than 25 years’ expertise of Genethon, Yposkesi invests significantly in innovation in bioprocessing to deliver on high-quality projects, cost-effectively.

Yposkesi has also entered into several strategic partnerships including those with Axovant Gene Therapies, Servier and Orchard Therapeutics.

www.yposkesi.com

Record changed: 2024-06-05